1. Red-hot biotechs to take spotlight at ASH virtual meeting — Moderna's 3-month data raise hopes for COVID-19 vaccine durability — BioNTech founder vaults into world's 500 richest — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Is Johnson & Johnson a ‘sell’ in 2018?

Discussion in 'Johnson & Johnson' started by anonymous, Mar 7, 2018 at 11:37 AM.

  1. anonymous

    anonymous Guest

    Johnson & Johnson may not be having a great 2018 so far with the stock ticking down about 8% since the year started. But is it time to get rid of the world’s largest pharma company’s shares? Let’s see.
     

  2. anonymous

    anonymous Guest

    Any device could have a problem (as the current one making stock slide). Stock is a gamble not a sure bet. If you need the $ and want to sell than do so.
     
  3. anonymous

    anonymous Guest

    price doubled from $70 to $140 from 2011 to 2017. I got out @ $135 after a great run. It will have another great run, just not now.
     
  4. anonymous

    anonymous Guest

    stock price will be steady in 2018 due to keeping the tax cut dollars for themselves, in 2019 the bottom will fall out due to 2018 complacency and more lawsuits